GlassScriptPhysician profile
Karen R Ringwald
NPI 1922075084
$3,407.73
in general payments reported to CMS, 2019-2025
22 companies · $865 in 2025
The $865 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $226 · 2021: $271 · 2022: $396 · 2023: $591 · 2024: $583 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.53 |
| Education | $229.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,149.25 | 2020-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $588.49 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $356.77 | 2019-2025 | |
| Janssen Biotech, INC. | $307.90 | 2019-2025 | Tremfya |
| Pfizer INC. | $192.29 | 2019-2024 | |
| Ucb, INC. | $138.75 | 2019-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $133.44 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $129.21 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $81.79 | 2019-2022 | |
| Lilly USA, LLC | $47.63 | 2024-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $43.41 | 2025 | Saphnelo |
| Genentech USA, INC. | $33.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $31.04 | 2019-2021 | |
| Genzyme Corporation | $30.18 | 2020 | |
| Octapharma USA, INC. | $22.32 | 2025 | Octagam Immune Globulin (Human) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $21.93 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.57 | 2019 | |
| Sandoz INC. | $18.63 | 2024 | Hyrimoz |
| Radius Health, INC. | $18.08 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2020 | |
| Celgene Corporation | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Ringwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.